We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Following FDA Meeting, Tonix Plans Two Phase III PTSD Trials
Following FDA Meeting, Tonix Plans Two Phase III PTSD Trials
Tonix Pharmaceuticals reported that the FDA has accepted the company’s proposed Phase III studies and planned NDA data package, following an end-of-Phase II meeting on its sublingual tablet for the treatment of post-traumatic stress disorder, TNX-102 SL.